ERI2: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: ERI2

NCBI ID: G112479

ERI2: A Potential Drug Target Or Biomarker for Various Diseases

ERI2 (Erb2 gene) is a protein that is expressed in various tissues of the body, including the brain, heart, and blood vessels. It is a member of the E-cadherin gene family, which is known for its role in cell-cell adhesion.

The ERI2 protein has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. This is because of its expression in a variety of tissues and the evidence that it plays a role in the development and progression of these diseases.

One of the key functions of the ERI2 protein is its role in cell-cell adhesion. This is the process by which cells stick together to form tissues and organs. In the brain, ERI2 is involved in the formation of the blood-brain barrier, which is a barrier that separates the brain from the surrounding blood vessels and helps to protect it from the harmful effects of drugs and other substances.

Additionally, ERI2 has also been shown to play a role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and other abnormalities in the brain.

Another potential mechanism by which ERI2 may contribute to the development of these diseases is its role in the regulation of the blood-brain barrier. The blood-brain barrier is a complex system that helps to protect the brain from the harmful effects of drugs and other substances. However, some studies have suggested that the ERI2 protein may help to breach this barrier, allowing drugs and other substances to enter the brain and contribute to the development of neurodegenerative diseases.

Additionally, ERI2 has also been shown to play a role in the regulation of cell proliferation and survival. This is the process by which cells grow, divide, and adapt to their environment. In cancer, the ERI2 protein is often expressed at higher levels than in normal tissues and has been shown to contribute to the growth and survival of cancer cells.

This suggests that targeting the ERI2 protein may be a promising strategy for the development of new treatments for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. Additionally, because ERI2 is also expressed in various tissues of the body, it may also be a potential biomarker for these conditions.

Overall, the ERI2 protein is a fascinating protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in these conditions and to develop new treatments.

Protein Name: ERI1 Exoribonuclease Family Member 2

More Common Targets